NASDAQ · SENS
Healthcare · Medical - Devices
$9.75
Down-$0.41 (-4.15%)
Updated Oct 30, 2026, 7:06 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SENS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
SENS closed at $9.75 after 21 trading sessions, down 2.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $9.30 | $9.75 | $9.175 | $9.75 | 522.68K |
| Oct 28, 2026 | $8.34 | $9.39 | $8.20 | $9.34 | 998.9K |
| Oct 27, 2026 | $7.48 | $8.45 | $7.40 | $8.33 | 824.65K |
| Oct 26, 2026 | $7.56 | $7.76 | $7.43 | $7.48 | 489.4K |
| Oct 23, 2026 | $7.32 | $7.62 | $7.25 | $7.51 | 477.36K |
| Oct 22, 2026 | $7.87 | $8.00 | $7.30 | $7.40 | 537.84K |
| Oct 21, 2026 | $8.23 | $8.34 | $7.9445 | $7.97 | 530.58K |
| Oct 20, 2026 | $8.02 | $8.40 | $7.92 | $8.21 | 366.24K |
| Oct 19, 2026 | $7.82 | $8.04 | $7.76 | $8.015 | 417.8K |
| Oct 16, 2026 | $8.23 | $8.23 | $7.75 | $7.77 | 609.19K |
| Oct 15, 2026 | $8.08 | $8.27 | $7.90 | $8.23 | 678.25K |
| Oct 14, 2026 | $8.80 | $8.84 | $8.0545 | $8.10 | 726.58K |
| Oct 13, 2026 | $9.26 | $9.26 | $8.88 | $8.92 | 518.69K |
| Oct 12, 2026 | $8.97 | $9.35 | $8.96 | $9.24 | 452.24K |
| Oct 9, 2026 | $9.02 | $9.04 | $8.78 | $8.98 | 499.32K |
| Oct 8, 2026 | $9.04 | $9.12 | $8.7829 | $9.02 | 765.69K |
| Oct 7, 2026 | $9.83 | $9.83 | $9.1105 | $9.16 | 637.68K |
| Oct 6, 2026 | $10.38 | $10.55 | $9.8707 | $9.96 | 568.8K |
| Oct 5, 2026 | $9.83 | $10.36 | $9.5856 | $10.31 | 709.56K |
| Oct 2, 2026 | $10.04 | $10.09 | $9.78 | $9.88 | 705.95K |
| Oct 1, 2026 | $10.10 | $10.19 | $9.90 | $9.96 | 606.44K |
The latest Smart Investors Daily articles mentioning SENS.
Company
Market Activity
Research & News
SENS research
Company profile and research snapshot.
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | TD Cowen | Buy | — |
| Oct 7, 2026 | Barclays | Equal-Weight | — |
| Jul 15, 2026 | Mizuho | Outperform | — |
| May 12, 2026 | HC Wainwright & Co. | Buy | — |
| May 11, 2026 | Stifel | Hold | — |
No generated briefing is available yet.
Yahoo · Oct 28, 2026
Claritev Corporation (CTEV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Benzinga · Oct 27, 2026
TD Cowen analyst Joshua Jennings reiterates Senseonics Holdings (NASDAQ:SENS) with a Buy and maintains $15 price target.
Yahoo · Oct 26, 2026
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028 Built on the proven sensing technology behind Eversense 365 and supported by encouraging preclinical data to reduce development risk GERMANTOWN, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a diabetes company redefining continuous glucose monitoring (CGM) with long-term implantable sensing tec
Benzinga · Oct 26, 2026
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028Built on the proven sensing technology behind
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SENS.
